Clinically significant reduction in psychological distress seen at three months with digital intervention
WEDNESDAY, Sept. 17, 2025 (HealthDay News) — A digital psychological intervention is safe and effective for individuals with inflammatory rheumatic diseases (IRDs), according to a study published online Sept. 9 in JAMA Network Open.
Johannes Knitza, M.D., Ph.D., from Philipps-Universität Marburg in Germany, and colleagues assessed whether a digital psychological intervention improves psychological outcomes and quality of life in patients with IRDs. The analysis included 102 patients with IRDs randomly assigned to receive the digital intervention or treatment as usual.
The researchers found that the intervention group had a significantly greater reduction in psychological distress at the three-month follow-up (least-squares mean difference, −3.60; Cohen d = −0.71) and a greater improvement for quality of life (least-squares mean difference, 0.04; Cohen d = 0.49). For psychological distress, a significantly greater number of participants in the intervention group experienced clinically meaningful improvement (59.2 versus 34.0 percent). Similar results were seen for quality of life (55.1 versus 32.0 percent) compared with the control group. A similar pattern was seen for secondary outcomes except for functional impairment. No intervention-related adverse events were seen.
“These findings suggest that such digital interventions could be a valuable, scalable approach to addressing mental health needs in rheumatology,” the authors write.
Several authors disclosed ties to relevant organizations.
Risk for Psychiatric Disorders Begins to Increase Before Diagnosis of IBD
Breathing Interventions May Curb Cravings With Substance Use
Adult Children of Divorced, Unmarried Parents Face More Mental Health Issues
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Consensus Statements Developed for Rheumatoid Arthritis-Linked Interstitial Lung Disease
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis